Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Brainstorm Cell Therapeutics, Inc’s stock clocked out at $1.18, down -4.84% from its previous closing price of $1.24. In other words, the price has decreased by -$4.84 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
To gain a deeper understanding of BCLI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.21 and its Current Ratio is at 0.21.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 01 ’24 when Lebovits Chaim bought 1,836 shares for $3.43 per share. The transaction valued at 6,292 led to the insider holds 80,960 shares of the business.
Lebovits Chaim bought 22,000 shares of BCLI for $5,016 on Sep 30 ’24. The President & CEO now owns 1,186,865 shares after completing the transaction at $0.23 per share. On Jul 19 ’24, another insider, Dagher Ibrahim B., who serves as the Chief Medical Officer of the company, sold 63,000 shares for $0.35 each. As a result, the insider received 22,069 and left with 0 shares of the company.
Stock Price History:
Over the past 52 weeks, BCLI has reached a high of $10.05, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is -1.21%, while the 200-Day Moving Average is calculated to be -45.85%.
Shares Statistics:
A total of 7.91M shares are outstanding, with a floating share count of 6.17M. Insiders hold about 22.32% of the company’s shares, while institutions hold 12.88% stake in the company.
